Momentum In Women’s Health, But Big Obstacles Too

Unmet Need In Space Was A Theme At J.P. Morgan

Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.

Women’s health remains a big area of unmet medical need and since women make up half the population, the commercial opportunity is enormous, but investment in therapeutics for women – whether for female-specific conditions like endometriosis and menopause or broader areas of health – continues to be underwhelming.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

10 Apr 2025

• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Cosette Bolsters Women’s Health, Dermatology Portfolios With Mayne Buyout

21 Feb 2025

• By Joseph Haas

Deal Snapshot: Cosette will acquire struggling Mayne Pharma for about $430m, thereby augmenting its women’s health and dermatology portfolio and enhancing commercial capabilities.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

21 Feb 2025

• By Eleanor Malone

Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.